Investor Relations


Common Stock

Data as of

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Company Overview

We aspire to become a world leader in AI-immunology, decoding the human immune system to develop effective immunotherapies for cancer and infectious diseases based on deep biological insights. We believe our ground-breaking AI-immunology platforms PIONEER, EDEN and RAVEN, trained to simulate the immune system, can be harnessed to rapidly and cost effectively design and develop unique immunotherapies, thereby potentially revolutionizing the process of drug discovery and development. We have two patient-specific cancer immunotherapies in the clinic and are advancing a portfolio of vaccines to treat bacterial and viral infections. With an experienced management team, strong IP portfolio and scalable business model, Evaxion is well positioned for rapid growth.

Are you eager to deep-dive into Evaxion's business?
Download our company presentation below, or click here to see all our latest presentations.

Latest News

Press Release

May 31, 2023

Evaxion Announces Business Update and First Quarter 2023 Financial Results

Press Release

May 25, 2023

Evaxion unveils proprietary genetic adjuvant technology to boost the effect of DNA and mRNA vaccines

Press Release

May 25, 2023

Evaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01

Press Release

May 16, 2023

Evaxion to host R&D Day on May 25, 2023




Subscribe to Investor Email Alerts

Be the first to know about news, milestones and events at Evaxion by subscribing to our investor email alerts.